Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis with Trial Sequential Analysis

Vicky Muller Ferreira, MD; Victor Ayres Muller, MD

2026-01-29

Contents

1 Abstract

Objective: To assess the effects of SGLT2 inhibitors on cardiovascular outcomes in HFpEF/HFmrEF.

Design: Systematic review, random-effects meta-analysis using Hartung-Knapp, and trial sequential analysis (TSA).

Data sources: MEDLINE, Embase, and CENTRAL; searches updated through August 13, 2025.

Eligibility criteria: Parallel-group randomized trials enrolling adults with LVEF 40% (HFmrEF 40-49%; HFpEF 50%).

Main outcome measures: Time-to-event composite of cardiovascular death or first heart failure hospitalization (primary); Kansas City Cardiomyopathy Questionnaire (KCCQ-TSS), components, and safety (secondary).

Results: Two dedicated HFpEF trials (n=12,251) reported the primary outcome. The pooled hazard ratio was 0.80 (95% CI 0.73-0.87; I^2=0%; ^{2} 0; 95% prediction interval 0.67–0.96). TSA crossed efficacy boundaries and exceeded the diversity-adjusted required information size, indicating conclusive evidence for the composite. Effects were consistent in patients with and without diabetes and across EF 40-49% vs 50% (no significant interactions). KCCQ improved (+2.3 points, 95% CI 1.0–3.6; responders 5 pts: 42% vs 38%). Safety showed more genital mycotic infections, with no increase in serious adverse events or acute kidney injury.

Conclusions: SGLT2 inhibitors robustly reduce cardiovascular death/heart failure hospitalization and improve health status in HFpEF/HFmrEF, supporting their role as foundational therapy, irrespective of diabetes status; effects on mortality alone remain imprecise.

Registration: PROSPERO CRD420251167908. Data and code: https://doi.org/10.5281/zenodo.18409428

Word count: 240 words

PROSPERO: CRD420251167908
Data availability: https://doi.org/10.5281/zenodo.18409428

2 Introduction

Heart failure with preserved ejection fraction (HFpEF) represents approximately 50% of all heart failure cases, with substantial morbidity, mortality, and healthcare costs[1-3]. Unlike heart failure with reduced ejection fraction where multiple therapies show mortality benefit, HFpEF has lacked effective pharmacological interventions[4-6].

The pathophysiology of HFpEF involves systemic inflammation, endothelial dysfunction, myocardial fibrosis, and metabolic dysregulation[7,8]. Previous trials of neurohormonal antagonists including ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid antagonists showed no convincing benefits[9-11]. The PARAGON-HF trial of sacubitril-valsartan narrowly missed its primary endpoint[12].

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed for diabetes, have shown cardiovascular benefits beyond glycemic control[13,14]. Proposed mechanisms include natriuresis, improved myocardial energetics, reduced inflammation, and favorable cardiac remodeling[15-17]. Following success in heart failure with reduced ejection fraction[18,19], recent trials evaluated SGLT2 inhibitors specifically in HFpEF populations.

Individual trials vary in populations, specific agents, and outcomes. Additionally, the conclusiveness of accumulated evidence requires formal assessment through trial sequential analysis to account for random error risk in cumulative meta-analyses[20].

We conducted a systematic review and meta-analysis to evaluate SGLT2 inhibitors' efficacy and safety in HFpEF, employing TSA to determine whether evidence has reached required information size for definitive conclusions.

3 Methods

3.1 Protocol and Registration

This systematic review followed PRISMA 2020 guidelines[21]. The protocol was registered in PROSPERO (CRD420251167908).

3.2 Search Strategy

We searched MEDLINE, Embase, Cochrane CENTRAL, and ClinicalTrials.gov from inception through August 13, 2025. Search terms included SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, sotagliflozin, luseogliflozin) combined with heart failure and preserved ejection fraction terms. Complete search strings are in the Supplement.

3.3 Study Selection

3.3.1 Inclusion Criteria

- Randomized controlled trials
- Adults with HFpEF/HFmrEF (LVEF 40%); prespecified stratification 40-49% vs 50%
- SGLT2 inhibitor versus placebo/control
- Clinical outcomes reported
- Minimum 3-month follow-up

3.3.2 Exclusion Criteria

- Duplicate publications/secondary analyses
- Predominantly HFrEF (LVEF <40%)
- No clinical outcomes
- Sample size <35 patients

For the primary composite outcome of cardiovascular death or heart failure hospitalization, we restricted analysis to dedicated HFpEF/HFmrEF trials. Other studies contributed to secondary outcomes (quality of life, safety).

3.4 Data Extraction and Risk of Bias

Two reviewers independently extracted data and assessed risk of bias using Cochrane RoB 2.0 tool[22].

3.5 Outcomes

Primary outcome: Composite of cardiovascular death or heart failure hospitalization
Secondary outcomes: Individual components, all-cause mortality, quality of life (KCCQ-TSS), 6-minute walk distance, safety events

3.6 Statistical Analysis

3.6.1 Meta-Analysis

We used restricted maximum likelihood (REML) estimation with Hartung-Knapp adjustment for random-effects models[23]. Heterogeneity was assessed using I² statistic, ², and 95% prediction intervals[24].

3.6.2 Numbers Needed to Treat

NNT was calculated for a 1-year horizon using survival transformation. For baseline 1-year risk R =0.096, survival S =0.904. Given HR=0.80, S (t)=S (t)$^{HR=0.904}$0.80=0.922, thus R =0.078. Absolute risk reduction at 1 year 1.73%; NNT 58 patients/year (CER 9.6%, HR-to-risk transformation).

3.6.3 Trial Sequential Analysis

TSA parameters: =0.05, power=80%, control event rate=9.6%, anticipated relative risk reduction=20%, diversity-adjusted for heterogeneity[25]. We calculated required information size (RIS) and performed sensitivity analysis with 15% RRR.

3.6.4 Subgroup and Sensitivity Analyses

Pre-specified subgroups: SGLT2 inhibitor type, diabetes status, baseline LVEF (50% vs 40-49%). Sensitivity analyses: leave-one-out, risk of bias restriction, fixed-effects models.

3.6.5 Publication Bias

For outcomes with 10 studies only, we assessed funnel plot asymmetry and performed Egger's test[26].

All analyses used R version 4.3.0 with meta and metafor packages.

4 Results

4.1 Study Selection

Records identified: 766 (MEDLINE 427; CENTRAL 298; CT.gov 41); after duplicates: 537; full-text assessed: 208; included: 15; primary outcome: 2 dedicated HFpEF/HFmrEF trials (DELIVER and EMPEROR-Preserved) that reported time-to-event data (Figure 1). Other studies contributed to secondary and safety outcomes.

4.2 Study Characteristics

Primary outcome analysis (2 dedicated HFpEF trials, n=12,251): - DELIVER (2022): Dapagliflozin, n=6,263, LVEF 54.2%, follow-up 27.6 months - EMPEROR-Preserved (2021): Empagliflozin, n=5,988, LVEF 54.3%, follow-up 26.2 months

Additional studies (n=13) contributed to secondary outcomes: Quality of life (PRESERVED-HF, CHIEF-HF), safety analyses (all 15 studies)

Mean age: 71.8 years; Women: 44.3%; Diabetes: 46.7%; Mean LVEF: 54.3%

4.3 Risk of Bias

Both primary outcome trials (DELIVER and EMPEROR-Preserved) were assessed as low risk of bias using the Cochrane RoB 2.0 tool.

4.4 Primary Outcome

SGLT2 inhibitors significantly reduced cardiovascular death or heart failure hospitalization: - **HR 0.80 (95% CI 0.73-0.87; p<0.001) - Heterogeneity: I²=0%; ² 0 - 95% Prediction interval: 0.67-0.96 - Absolute risk reduction: 1.73% at 1 year - NNT: 58 patients per year**

4.5 Secondary Outcomes

- **HF hospitalization:** HR 0.73 (95% CI 0.67-0.80; p<0.001)
- **CV death:** HR 0.90 (95% CI 0.81-1.00; p=0.061)
- **All-cause mortality:** HR 0.95 (95% CI 0.87-1.04; p=0.28)
- **Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS):** +2.3 points (95% CI 1.0-3.6; p<0.001)
    - Responders (5 points): 42% vs 38% (control)

4.6 Subgroup Analyses

No significant interactions detected: - By drug: Dapagliflozin HR 0.82, Empagliflozin HR 0.79 (p-interaction=0.82) - By diabetes: With HR 0.79, Without HR 0.84 (p-interaction=0.45)
- By LVEF: 40-49% HR 0.80, 50% HR 0.83 (p-interaction=0.68)

4.7 Trial Sequential Analysis

TSA demonstrated conclusive evidence: - **Required information size: 8,385 patients (diversity-adjusted) - Current sample: 12,251 (146% of required) - Z-curve crossed monitoring boundary after EMPEROR-Preserved - Sensitivity with 15% RRR: Still conclusive (RIS=14,890)**

4.8 Safety

From all 15 studies contributing safety data (n=~22,000): - **Volume depletion:** RR 1.28 (95% CI 1.04-1.58); 12 more events per 1000 patient-years (NNH 83) - **Genital infections:** RR 2.23 (95% CI 1.45-3.44); 14 more per 1000 patient-years (NNH 71) - **Acute kidney injury:** RR 0.88 (95% CI 0.72-1.08) - **Ketoacidosis:** No events in HFpEF patients

5 Discussion

This systematic review and meta-analysis demonstrates that SGLT2 inhibitors robustly reduce cardiovascular events in HFpEF, with a 20% reduction in the composite of cardiovascular death or heart failure hospitalization (HR 0.80). The trial sequential analysis confirmed conclusiveness: RIS 8,385 patients (diversity-adjusted) versus 12,251 accumulated (146% of RIS), with Z-curve crossing efficacy boundaries; results remained conclusive under a 15% RRR sensitivity.

5.1 Clinical Implications

The NNT of 58 patients per year represents clinically meaningful benefit (absolute risk reduction at 1 year: 1.73%; CER 9.6%, HR-to-risk transformation). While higher than some HFrEF therapies, this reflects the lower baseline risk in HFpEF populations. The effect was primarily driven by 27% reduction in heart failure hospitalizations. While cardiovascular mortality showed only a trend (HR 0.90), this mirrors HFrEF trials where hospitalization benefits preceded mortality benefits with longer follow-up[27].

Consistency across SGLT2 inhibitors (p-interaction=0.82) suggests a class effect, providing flexibility in drug selection. Similar efficacy in patients with and without diabetes (p-interaction=0.45) expands the eligible population, as approximately half of HFpEF patients lack diabetes[28].

5.2 Mechanistic Considerations

Multiple mechanisms likely contribute[29]: 1. **Hemodynamic:** Natriuresis without sympathetic activation 2. **Metabolic:** Enhanced ketone utilization and mitochondrial function 3. **Anti-inflammatory:** Reduced NLRP3 inflammasome activation 4. **Structural:** Favorable cardiac remodeling and reduced fibrosis 5. **Vascular:** Improved endothelial function

The minimal heterogeneity ($I^2 < 1\%$) suggests consistent mechanisms across populations.

5.3 Comparison with Previous Trials

Our findings contrast with failed HFpEF trials[9-12]: - PARAGON-HF: HR 0.87 (95% CI 0.75-1.01) - TOP-CAT: Regional variations, questionable patient selection - CHARM-Preserved, PEP-CHF, I-PRESERVE: No significant benefits

SGLT2 inhibitors' success may reflect targeting of metabolic dysfunction central to HFpEF pathophysiology, unlike pure neurohormonal antagonism.

5.4 Safety Profile

Volume depletion (12 more per 1000 patient-years, NNH 83) and genital mycotic infections (14 more per 1000 patient-years, NNH 71) were manageable. No increased acute kidney injury risk and absence of ketoacidosis in HFpEF populations are reassuring. Risk-benefit remains favorable (NNT 58/year vs NNH 71 for genital infections and 83 for volume depletion, corresponding to 14 and 12 more events per 1000 patient-years respectively).

5.5 Strengths and Limitations

Strengths: - Rigorous methodology (PRISMA 2020, RoB 2.0) - Minimal heterogeneity - TSA confirming conclusive evidence - Comprehensive sensitivity analyses

Limitations: 1. Protocol registration in PROSPERO PENDENTE 2. Mixed HFpEF/HFmrEF populations (addressed by subgroup analysis) 3. Variable follow-up duration (3-27 months) 4. Limited long-term safety data 5. Heterogeneity in baseline risk across trials

5.6 Future Directions

Research priorities include optimal patient selection, combination therapy evaluation, long-term outcomes, mechanistic studies, and real-world effectiveness assessment.

6 Conclusions

SGLT2 inhibitors robustly reduce cardiovascular events in heart failure with preserved ejection fraction, with an estimated number needed to treat of 58 patients per year (absolute risk reduction at 1 year: 1.73%; CER 9.6%, HR-to-risk transformation). Trial sequential analysis confirms conclusive evidence. The consistent benefit across subgroups and favorable safety profile support SGLT2 inhibitors as foundational therapy for HFpEF. These findings address a critical therapeutic gap for millions of patients with this challenging condition.

7 Tables

7.1 Table 1. Characteristics of Studies Included in Primary Outcome Analysis

Table 1: Primary outcome trials characteristics

Study	Year	Drug	Sample.Size	Follow.up..years.	Mean.Age	Female....	Diabetes....	Mean.LVEF....
DELIVER	2022	Dapagliflozin	3131/3132	2.3	71.7	43.9	45.2	54.2
EMPEROR-Preserved	2021	Empagliflozin	2997/2991	2.2	71.9	44.6	48.3	54.3

*Additional studies contributed to secondary and safety outcomes (see Supplement)

7.2 Table 2. Safety Outcomes (All 15 Studies)

Table 2: Safety outcomes from all included studies. NNH 71 for genital infections (14 more/1000 pt-yr) and 83 for volume depletion (12 more/1000 pt-yr).

Outcome	Risk.Ratio	X95..CI	Additional.Events.1000.pt.yr	NNH
Volume depletion	1.28	1.04-1.58	12	83
Genital infections	2.23	1.45-3.44	14	71
Acute kidney injury	0.88	0.72-1.08	-5	-
Ketoacidosis	No events	-	0	-

7.3 Table 3. GRADE Summary of Findings

Table 3: GRADE evidence summary

Outcome	Certainty	Effect.Size	Clinical.Impact
CV death/HF hospitalization	High	HR 0.80 (0.73-0.87)	NNT 58/year
HF hospitalization	High	HR 0.73 (0.67-0.80)	27% reduction
CV death	Moderate	HR 0.90 (0.81-1.00)	Trend to benefit
All-cause mortality	Low	HR 0.95 (0.87-1.04)	No significant effect
KCCQ-TSS	Moderate	MD +2.3 (1.0-3.6)	Small improvement
Safety	High	Acceptable	NNH >70

8 Figures

8.1 Figure 1. PRISMA Flow Diagram

8.2 Figure 2. Forest Plot - Primary Composite Outcome

8.3 Figure 3. Trial Sequential Analysis

8.4 Figure 4. Subgroup Analyses

PRISMA 2020 Flow Diagram

Figure 1: PRISMA 2020 Flow Diagram. Records identified: 766 (MEDLINE 427, CENTRAL 298, Clinical-Trials.gov 41); after duplicates: 537; full-text assessed: 208; included: 15; primary outcome: 2 dedicated HFpEF/HFmrEF trials.

Figure 2: Forest Plot of primary composite outcome (CV death or HF hospitalization). HR 0.80 (95% CI 0.73-0.87; I²=0%; ² 0; 95% PI 0.67-0.96); REML + Hartung-Knapp; Trials: DELIVER, EMPEROR-Preserved.

Figure 3: Trial Sequential Analysis. TSA: =5%, power=80%, CER=9.6%/yr, RRR=20% (sensitivity 15%); RIS=8,385 (diversity-adjusted); 12,251 accumulated (146% of RIS); Z-curve crossed efficacy boundaries.

Figure 4: Subgroup analyses showing consistent effects across patient characteristics. No significant interactions detected (p-interaction: drug type=0.82, diabetes=0.45, LVEF=0.68).

9 References

1. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14:591-602.

2. Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;124:1598-1617.

3. Tsao CW, Lyass A, Enserro D, et al. Temporal trends in heart failure with preserved and reduced ejection fraction. JACC Heart Fail. 2018;6:678-685.

4. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507-515.

5. Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction. Circulation. 2016;134:73-90.

6. Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016;375:1868-1877.

7. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction. J Am Coll Cardiol. 2013;62:263-271.

8. Shah SJ, Borlaug BA, Kitzman DW, et al. Research priorities for heart failure with preserved ejection fraction. Circulation. 2020;141:1001-1026.

9. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-781.

10. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345.

11. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467.

12. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609-1620.

13. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.

14. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.

15. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit. Diabetologia. 2018;61:2108-2117.

16. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 inhibitors. JACC Basic Transl Sci. 2020;5:632-644.

17. Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors. Circulation. 2022;146:1383-1405.

18. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008.

19. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-1424.

20. Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17:39.

21. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement. BMJ. 2021;372:n71.

22. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

23. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis. BMC Med Res Methodol. 2014;14:25.

24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.

25. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61:64-75.

26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.

27. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction. Lancet. 2020;396:819-829.

28. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT2 inhibitors in patients with heart failure. Lancet. 2022;400:757-767.

29. Butler J, Hamo CE, Filippatos G, et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail. 2017;19:1390-1400.

30. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089-1098.

31. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-1461.

32. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-1392.

33. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-3726.

34. Spertus JA, Jones PG. Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire. Circ Cardiovasc Qual Outcomes. 2015;8:469-476.

35. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.

10 Supplementary Material

Available online at: https://doi.org/10.5281/zenodo.18409428

10.1 Contents:

- Complete search strategies
- Full data extraction forms
- Extended statistical methods
- Additional sensitivity analyses
- Complete PRISMA checklist
- R code for all analyses

10.2 Data Sharing Statement

All extracted data and analysis scripts are available at https://doi.org/10.5281/zenodo.18409428. Individual patient data were not available for this analysis.

10.3 Patient and Public Involvement

Patients were not directly involved in this systematic review. Results will be disseminated through patient organizations and lay summaries.

10.4 Author Contributions

VMF: Conceptualization, methodology, data curation, formal analysis, writing - original draft, writing - review & editing. VAM: Methodology, validation, data curation, writing - review & editing. Both authors approved the final version of the manuscript.

10.5 Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

10.6 Conflicts of Interest

All authors declare no conflicts of interest.

Corresponding author: Vicky Muller Ferreira, MD (vickymuller@heartlandprotocol.org)
Last updated: 2026-01-29

PRISMA 2020 Flow Diagram

Trial Sequential Analysis for Primary Composite Outcome

Legend:
- Z-curve
- Efficacy boundary
- Futility boundary
- Conventional boundary
- RIS
- Current N

RIS = 8,385

Current N = 12,251
(146% of RIS)

EMPEROR−Preserved

DELIVER

Cumulative Z−Score

Cumulative Sample Size

Z−curve crossed efficacy boundary: Evidence is conclusive for benefit

Subgroup Analysis of Primary Outcome